ARANESP darbepoetin alpha (rch) 60 microgram/0.3mL injection syringe within a pen injector Australia - English - Department of Health (Therapeutic Goods Administration)

aranesp darbepoetin alpha (rch) 60 microgram/0.3ml injection syringe within a pen injector

amgen australia pty ltd - darbepoetin alfa, quantity: 200 microgram/ml - injection, solution - excipient ingredients: dibasic sodium phosphate; monobasic sodium phosphate monohydrate; sodium chloride; polysorbate 80; water for injections - aranesp is indicated for the treatment of anaemia associated with chronic renal failure (crf). aranesp is also indicated for the treatment of anaemia and reduction of transfusion requirements in patients with non-myeloid malignacies where anaemia develops as a result of concommitantly administered chemotherapy.